Thrivent Financial for Lutherans Acquires New Shares in Humacyte, Inc. (NASDAQ:HUMA)

Thrivent Financial for Lutherans bought a new position in shares of Humacyte, Inc. (NASDAQ:HUMA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 130,894 shares of the company’s stock, valued at approximately $712,000. Thrivent Financial for Lutherans owned about 0.11% of Humacyte at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Millennium Management LLC raised its stake in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after acquiring an additional 1,334,641 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Humacyte by 28.7% in the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after buying an additional 896,415 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after buying an additional 524,600 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Humacyte by 3,301.5% during the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after buying an additional 450,031 shares during the period. Finally, Deerfield Management Company L.P. Series C acquired a new position in Humacyte in the 2nd quarter valued at $1,550,000. 44.71% of the stock is currently owned by institutional investors.

Humacyte Price Performance

NASDAQ:HUMA opened at $4.25 on Wednesday. The company has a market capitalization of $534.91 million, a price-to-earnings ratio of -3.17 and a beta of 1.38. The company has a 50-day moving average of $5.17 and a 200-day moving average of $6.13. Humacyte, Inc. has a 52 week low of $2.45 and a 52 week high of $9.97. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10.

Analyst Ratings Changes

HUMA has been the subject of a number of recent analyst reports. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Thursday, November 21st. TD Cowen restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Piper Sandler set a $6.00 price target on Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Humacyte has a consensus rating of “Buy” and a consensus target price of $13.00.

Insiders Place Their Bets

In other news, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the transaction, the director now owns 40,276 shares in the company, valued at approximately $217,490.40. The trade was a 11.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Laura E. Niklason sold 157,704 shares of Humacyte stock in a transaction on Monday, September 9th. The shares were sold at an average price of $5.42, for a total value of $854,755.68. Following the completion of the transaction, the chief executive officer now owns 3,519,558 shares of the company’s stock, valued at approximately $19,076,004.36. The trade was a 4.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,662,886 shares of company stock worth $7,489,538 over the last quarter. Company insiders own 11.20% of the company’s stock.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.